

PG01

## Chemical Properties


CAS No. : 853138-65-5

Formula: C<sub>28</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub>

Molecular Weight: 439.55

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	PG01 is a potent CFTR Cl-channel potentiator, effective against ΔF508 (K <sub>a</sub> 0.3 μM), and also against E193K, G970R and G551D (CFTR mutants), with K <sub>d</sub> values of 0.22 μM, 0.45 μM and 1.94 μM, respectively. PG01 increases ΔF508-CFTR Cl- currents upon addition of forskolin. F508-CFTR Cl-current upon addition of Forskolin, correcting the gating defect of CFTR mutants.
Targets(IC50)	CFTR
In vitro	PG01 induces significant currents in cells expressing either G551D- or G1349D-CFTR. While PG01 alone does not activate ΔF508-CFTR, it notably enhances ΔF508-CFTR Cl-current in the presence of Forskolin (0.5 and 2 μM). At a concentration of 100 nM, PG01 markedly increases channel activity, evidenced by frequent channel openings. The compound's effectiveness in activating G551D-CFTR, with an apparent K <sub>d</sub> of 1 μM, is roughly 100 times greater than that of genistein, and its potency in activating G1349D-CFTR is superior, requiring only 40 nM. These currents are blocked by CFTRinh-172 and absent in nontransfected cells, indicating specificity for CFTR modulation.[1]
In vivo	Microsome metabolism studies and rat pharmacokinetic analysis indicate that PG01 metabolizes significantly faster than SF-03. The pharmacokinetics of PG01 in rats were assessed through serial plasma concentration measurements following single bolus infusions (5 mg/kg), revealing that its pharmacokinetics adhere to a two-compartment model with elimination half-times of less than 5 minutes and 130 minutes, and a distribution volume of 4 L.[1]

## Solubility Information

Solubility	DMSO: 30 mg/mL (68.25 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	2.2751 mL	11.3753 mL	22.7505 mL
5 mM	0.455 mL	2.2751 mL	4.5501 mL
10 mM	0.2275 mL	1.1375 mL	2.2751 mL
50 mM	0.0455 mL	0.2275 mL	0.455 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Pedemonte N, et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. *Mol Pharmacol.* 2005 May;67(5):1797-807.  
Caputo A, et al. Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators. *J Pharmacol Exp Ther.* 2009 Sep;330(3):783-91.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481